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Abstract: A combination of mesenchymal stem cells (MSCs) and scaffolds seems to be a promising
approach for meniscus repair. To facilitate the search for an appropriate scaffold material a reliable
and objective in vitro testing system is essential. This paper introduces a new scoring for this purpose
and analyzes a hyaluronic acid (HA) gelatin composite scaffold and a polyurethane scaffold in
combination with MSCs for tissue engineering of meniscus. The pore quality and interconnectivity
of pores of a HA gelatin composite scaffold and a polyurethane scaffold were analyzed by surface
photography and Berliner-Blau-BSA-solution vacuum filling. Further the two scaffold materials
were vacuum-filled with human MSCs and analyzed by histology and immunohistochemistry after
21 days in chondrogenic media to determine cell distribution and cell survival as well as proteoglycan
production, collagen type I and II content. The polyurethane scaffold showed better results than the
hyaluronic acid gelatin composite scaffold, with signs of central necrosis in the HA gelatin composite
scaffolds. The polyurethane scaffold showed good porosity, excellent pore interconnectivity, good
cell distribution and cell survival, as well as an extensive content of proteoglycans and collagen type
II. The polyurethane scaffold seems to be a promising biomaterial for a mesenchymal stem cell-based
tissue engineering approach for meniscal repair. The new score could be applied as a new standard
for in vitro scaffold testing.
Keywords: meniscus; polyurethane scaffold; composite scaffold; hyaluronic acid; collagen; gelatin;
chondrogenesis; human mesenchymal stem cells; biocompatibility
1. Introduction
Lesions of the meniscus are amongst the most frequent injuries in orthopedic surgery [1]. In many
cases partial meniscectomy has to be performed due to the poor healing capacity of the avascular part
of the meniscus [2]. This however predisposes for osteoarthritic changes of the affected knee joint [2–4].
Knee menisci are essential in providing joint stability [5], lubrication [6], proprioception [7], force
transmission [8], and shock absorption [9]. Additionally, partial meniscectomy causes severe changes
in the biomechanics of the knee joint that are directly proportional to the amount of lost tissue [10]
resulting in drastically increased contact pressure to the surrounding cartilage [11]. Therefore, it is
essential to restore as much meniscus substance as possible. While successful repair strategies for
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lesions in the vascular part of the meniscus have been developed, there is still no sufficient therapy
for lesions in the avascular part [12]. Currently two scaffolds are used in clinic in a cell-free approach
for meniscus repair: CMI®, a collagen scaffold, and Actifit®, a polyurethane scaffold. Both scaffolds
have shown promising results [1,13–15], however, as of yet no large randomized studies with control
groups have been published. Recently, mesenchymal stem cells have been a focus of attention in
newly developed approaches for meniscus repair [15]. As these cells have both the potential to
differentiate into fibro chondrocytes and the ability to secrete repair promoting growth factors they
seem an ideal tool for meniscus repair [16]. Preclinical studies have already shown the repair potential
of mesenchymal stem cells in combination with a scaffold in the treatment of relatively small tears
and punch defects in the avascular zone of the meniscus [17–19]. A recent review article highlights
the capability of cells to enhance meniscus repair, however, it remains unclear which biomaterial is
best suited for this purpose [20]. With new scaffold materials evolving, costly animal experiments
have to be conducted before putting them into clinical trials. To save time, resources and animals, a
reliable in vitro testing system is needed to single out promising materials before going into in vivo
experiments. The object of this paper is to thoroughly test two biomaterials for their suitability to
be used in a mesenchymal stem cell based approach for tissue engineered meniscus. Both to rank
our own results as well as to introduce a new standard for biomaterial testing we created a scoring
system. We tested the polyurethane scaffold Actifit® that has already shown promising results in
clinical trials [1], as well as a hyaluronic acid gelatin composite scaffold that has shown good results in
several in vivo experiments [19].
2. Materials and Methods
2.1. Production of Composite Scaffolds
Hyaluronic acid gelatin composite scaffolds were produced as described elsewhere [21,22]. Briefly,
the material contained 70% hyaluronic acid (commercially available product, Jaloskin®, Fidia Advances
Biopolymers, Abano Terme, Italy) and 30% gelatin (hydrolyzed bovine collagen, Sigma, Seelze,
Germany). To obtain a porous material solvent casting particulate leaching technique was applied.
Both components were solved, mixed, and air dried after the addition of NaCl-chrystals. Salt was
washed out with water and the material was then dried in vacuum. Pore size was 350–450 µm.
The product was cut in smaller parts and then sterilized with 25 kGy beta rays (Beta-Gamma-Service
GmbH, Saal, Germany).
2.2. Polyurethane Scaffolds
The commercially available polyurethane scaffold Actifit® (Orteq, London, UK) was used
for this study. The product was cut in smaller parts and then sterilized with 25 kGy beta rays
(Beta-Gamma-Service GmbH, Saal, Germany).
2.3. Macroscopic Assessment of Scaffold Pore Structure
For each biomaterial a whole biomaterial meniscus was cut into 2 mm thick slices whose surfaces
were subsequently photographed. Using highly-magnified and printed photographs, the quality the
pore structure was assessed by two blinded and experienced scorers. Scorers conducted this by using
the naked eye to get a quick and simple overview, enabling a semi-quantitative analysis.
2.4. Interconnectivity of Scaffold Pores
For each biomaterial two 2 mm thick slices were filled with a Berliner-Blau-BSA-solution
containing 10% Berliner Blau and 10% BSA in distilled water. Filling was conducted by vacuum
as described below. Filled scaffolds were fixated overnight in phosphate buffer 0.1 M with 4%
paraformaldehyde and 1% glutaraldehyde and embedded in TissueTek® (Sakura Finetek Japan Co.,
Tokyo, Japan) the following day using liquid nitrogen. Blocks were cut in the cryotome and their
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surfaces were repeatedly photographed after each 100 µm cut in order to create a representative series of
images. The Berliner-Blau-BSA-solution was only found in pores that had indirect access to the surface
of the scaffold and were, thus, interconnected. A qualitative assessment of the interconnectivity was
conducted by two blinded and experienced scorers. Scorers used the naked eye to semi-quantitatively
determine the percentage of interconnected pores, which is equivalent to the percentage of the scaffold
area that shows the typical Berliner-Blau color.
2.5. Isolation and Culture of Human Mesenchymal Stem Cells
After approval by the local ethical committee and patients’ informed consent, bone
marrow-derived MSCs were acquired from patients with surgery that included harvest from the
iliac crest.
Mononuclear cells were layered over the Ficoll-Paque (GE Healthcare Bio-Sciences, Marlborough,
MA, USA) density-gradient. A heparinized syringe was used to aspirate the layer with MSCs,
Dulbecco’s modified Eagle’s medium (DMEM), low glucose concentration (5%), with 10% fetal bovine
serum, 1% penicillin, and 1% Hepes buffer was added and 2 ˆ 106 nucleated cells were plated per
T75 cell culture dish. The adherent cells expanded quickly and media was changed twice a week until
reaching of 80% confluence.
2.6. In Vitro Chondrogenesis
Upon reaching 80% confluence mesenchymal stem cells were trypsinized, counted, washed, and
re-suspended in a chemically-defined chondrogenic medium to final concentration of 2 ˆ 104 cells/µL.
As previously described by Angele et al. [23] chondrogenic media contained DMEM (high glucose),
200 µM ascorbic acid-2 phosphate, 1% insulin-transferrin-sodium selenite media supplement (ITS)
(both from Sigma, Taufkirchen, Germany), 1 mM pyruvate, 100 nM dexamethasone, and 10 ng/mL
transforming growth factor ß1(TGFß1) (R and D systems, Wiesbaden, Germany).
Cylindric (diameter: 5 mm, height: 2 mm) scaffold parts were then loaded with 50 µL of the
cell suspension (1 ˆ 106 cells) per scaffold part. From each biomaterial, 6–12 scaffolds were loaded.
Loading of the scaffolds was achieved using a rotary valve vacuum pump (Vacuubrand GmbH,
Wertheim, Germany). Both scaffold and cell suspension were placed into cylindrical tubes. Vacuum
was then applied for 10 s, followed by a brief ventilation. This was repeated 10 times. The strength of
the applied vacuum was adjusted manually to an extent that showed moderate foam generation in
the media.
The loaded scaffolds were then incubated at 37 ˝C for 1 h and five scaffolds of each biomaterial
were then kept in chondrogenic media for 21 days under normoxic conditions, media was changed
three times a week. Per biomaterial, one scaffold was fixated on the next day, serving as a
loading control.
2.7. Histology
The scaffolds from the in vitro differentiation were fixed in a 1 M phosphate buffer solution
containing 4% paraformaldehyde, embedded in Tissue-Tek OCT (Sakura Finetek, Tokyo, Japan) and
frozen in liquid nitrogen. All samples were cut in 10 µm sections and every 10th of them was stained
with dimethylmethylen blue (DMMB). Two blinded scorers analyzed the sections according to the
proposed scoring system. This was conducted by the naked eye to assess semi-quantitative differences.
Both scorers were experienced in analyzing histological cartilage sections.
To evaluate the cell viability we searched for secure histological signs of cell death, such as blurred
cell nucleus borders and loss of adherence. Cell distribution was assessed by comparing the number
of cell-populated pores to the number of cell-free pores. The content of proteoglycan was measured by
determining the percentage of metachromatic extracellular matrix in scaffold pores.
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2.8. Immunohistochemistry
Sections were washed followed by a 15 min digestion with 0.1% pepsin at pH 3.5 for a
facilitated antibody access to the target epitopes. Type I and II collagen were immunolocalized
by the immunoperoxidase ABC technique (Vector, Burlingame, CA, USA). As primary antibodies
anti-collagen II (clone II-4C11; Calbiochem Merck, Schwalbach, Germany) and monoclonal CD31
mouse anti-rabbit antibodies (clone JC-70A IgG1 light chain type kappa; Abcam, Cambridge, UK)
were used. After staining with biotin conjugated polyclonal goat anti mouse IgG secondary antibody
(Jackson, West Grove, PA, USA), positive signals were visualized by nickel- and cobalt-enhanced
3,31-diaminobenzidine (DAB). Two blinded scorers analyzed the sections semi-quantitatively according
to the proposed scoring system. Percentage of content of collagen I or collagen II was determined by
comparing DMMB stained slides with immunohistochemically stained slides.
2.9. Score
To our knowledge as of yet there has not been described a score for standardized in vitro analysis
and comparison of newly developed biomaterial for stem cell-based meniscus repair. Therefore, we
propose the following score.
For scoring item 1, magnified photographs of the surface of the biomaterial slices were analyzed.
Berliner-Blau-solution filled biomaterial slices were analyzed for scoring item 2.
For scoring items 3–7, five to ten scaffolds per biomaterial were analyzed after being filled with
MSCs and 21 days of differentiation in chondrogenic media.
Further details about assessing the scoring values’ different parameters are outlined in the
above paragraphs.
Each of this scaffolds was assessed on its own for each scoring item and the average scoring value
was noted as a whole number value in the score. Scoring values are displayed in Table 1.
Table 1. Scoring system for analysis of biomaterials used for meniscal substitution or tissue engineering
of the meniscus.
Scoring Value 0 1 2 3




















0% 1%–25% 26%–75% More than 75%
Cell distribution in scaffolds
(in vitro), percentage of
cell-populated pores
0% 1%–25% 26%–75% More than 75%
Cell viability in scaffolds




proteoglycan <25% 25%–75% >75%
Percentage of Collagen I
compared to total amount of
extracellular matrix
More than 75% 25%–75% <25% No staining forcollagen I
Percentage of Collagen II
content compared to total
amount of extracellular matrix
No staining for
collagen II <25% 25%–75% >75%
That way seven individual scoring subgroups were formed, each received a scoring value ranging
from 0 (bad) to 3 (ideal). The values of these items were summed up, consequently reaching a combined
score from 0 (material unsuitable for meniscus repair) to 21 (promising material for MSC-based
Materials 2016, 9, 276 5 of 14
meniscus repair). Two experienced blinded scorers conducted the data collection. A high internal
consistency has been attributed to this scoring system by a statistician from the Center of Clinical
Studies of the University of Regensburg, thus making it legitimate to sum up the single item scores.
2.10. Statistical Analysis
To determine whether data followed a Gaussian distribution a Kolmogorov–Smirnov test was
conducted. For comparison of non-normal distributed data the Mann–Whitney U-test was used.
A probability value of less than 0.05 was set as the level of statistical significance for all evaluations.
3. Results
We conducted a thorough test of two biomaterials, one being a hyaluronic acid gelatin composite
scaffold developed in our own working group, the other one being the commercially available
polyurethane based product Actifit® which is already in clinical use for cell-free meniscal replacement
after subtotal loss of meniscus substance.
3.1. Macroscopical Assessment of Scaffold Pore Structure
The biomaterials were cut into 2 mm thick slices to assess the quality of the porosity. Both the
hyaluronic acid gelatin composite scaffold as well as the Actifit® scaffold showed an even distribution
of pores that varied less than 50% in size (Figures 1 and 2).
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3.2. Interconnectivity of Scaffold Pores
To assess the interconnectivity of the scaffolds’ pores the scaffolds were filled with a
Berliner-Blau-BSA-solution that could only penetrate into interconnected pores. The hyaluronic
acid gelatin composite scaffold showed a very strong interconnectivity of pores with almost no pores
remaining unfilled. The Actifit® scaffold showed good interconnectivity of pores in the center of the
scaffold, however, many pores in the scaffold’s periphery remained unfilled (Figures 3 and 4).
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bar = 1 mm.
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3.3. In Vitro Chondrogenesis
To analyze the biocompatibility of the materials an in vitro experiment was conducted.
Per biomaterial six scaffold cylinders, 2 mm in height, and 5 mm in diameter were filled with human
MSCs and kept in chondrogenic media for 21 days.
Upon harvest the hyaluronic acid gelatin composite scaffolds appeared instable, sensitive to touch
with obvious signs of degradation. DMMB staining showed an initially excellent cell distribution
with more than 75% of pores being populated by cells. However, after 21 days the survival rate of
cells was unsatisfying, with an approximate average of 50% percent of cells showing signs of necrosis,
especially in the central parts of the scaffolds. Accordingly, only the peripheral pores of the scaffolds
were extensively filled with proteoglycans, whereas the central parts remained fairly empty. Figures 5
and 6 show representative DMMB-stained slices.
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The Actifit® scaffolds appeared stable upon harvest with no obvious signs of degradation. Initial 
cell distribution was excellent with more than 75% of pores being cell-populated. No signs of necrosis 
were observed. Throughout the whole scaffolds extensive production of proteoglycans was noted. 
Immunohistochemistry showed high levels of collagen type II and moderate levels of collagen type I 
content. Figures 7 and 8 show representatives slices with collagen type I immunohistochemistry. 
Collagen type II immunohistochemistry is displayed in Figures 9 and 10. 
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Figure 5. Representative histological slide of a hyaluronic acid gelatin composite scaffold after 21 days
of in vitro chondrogenesis with visible central necrosis. DMMB staining. Proteoglycan-rich extracellular
matrix appears red, scaffold parts appear blue. Magnification bar = 500 µm.
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Figure 6. Representative histological slide of an Actifit® scaffold after 21 days of in vitro chondrogenesis.
DMMB staining. Proteoglycan-rich extracellular matrix appears red, scaffold parts appear grey and
porous. Magnification bar = 500 µm.
Immunohistochemistry showed high levels of both collagen I and II in peripheral parts and
almost no collagen I or II in the central parts of the scaffolds.
The Actifit® scaffolds appeared stable upon harvest with no obvious signs of degradation. Initial
cell distribution was excellent with more than 75% of pores being cell-populated. No signs of necrosis
were observed. Throughout the whole scaffolds extensive production of proteoglycans was noted.
Immunohistochemistry showed high levels of collagen type II and moderate levels of collagen type
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I content. Figures 7 and 8 show representatives slices with collagen type I immunohistochemistry.
Collagen type II immunohistochemistry is displayed in Figures 9 and 10.
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3.4. Scoring
In our scoring system scaffolds receive an overall score ranging from 0 (=not suitable) to 21 (=very
promising). Both hyaluronic acid gelatin composite scaffold and Actifit® received promising results,
however, Actifit® still obtained a clearly higher total score of 19 points compared to the hyaluronic
acid gelatin composite scaffold’s 15 points (Figure 11).
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The hyaluronic acid gelatin composite scaffold received statistically significant less points  
(p < 0.05) for cell survival compared to Actifit®, because necrosis took place in the central parts of the 
hyaluronic acid gelatin composite scaffolds. The diminished number of vital cells consequently 
produced fewer proteoglycans and collagen II, thus leading to further point losses in these categories. 
The scoring results for cell viability are displayed in Figure 12. 
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4. Discussion
The main purpose of this paper is to introduce a new scoring system that can be universally
applied for in vitro testing of biomaterials for scaffold-based cell-enhanced meniscus repair.
To demonstrate the execution and validity of our score we used it to compare two scaffolds that
have been previously used both in an in vitro setting, an in vivo setting in an animal model [15,18,19,24].
One of the scaffolds is already clinically used in a cell-free approach [1].
We thoroughly analyzed two biomaterial scaffolds regarding their capacity for mesenchymal stem
cell-based meniscus repair: the polyurethane scaffold Actifit® and a hyaluronic acid gelatin composite
scaffold developed in our own working group. To objectify our results as well as to facilitate and
standardize further testing we introduced a new point-based scoring system for the in vitro testing of
biomaterial for meniscus repair.
In our test both scaffolds showed good results; however, Actifit® received a clearly better overall
score. The hyaluronic acid gelatin composite scaffold showed excellent porosity, however, cell
survival was limited with necrosis taking place in the central parts of the scaffolds. Consequently
less proteoglycans and collagens were produced. Actifit® received excellent results throughout our
test, this seems to support the argument that this scaffold should be further investigated in in vivo
experiments and clinical trials.
In existing clinical trials [1,15,25] as well as in in vivo experiments [26,27] Actifit® showed good
results with statistically significant improvements in clinical outcome as well as improved macroscopic
and histologic meniscus healing. The hyaluronic acid gelatin composite scaffold showed promising
results in several in vivo studies [18,19,23]. These good results of both scaffolds in in vivo experiments
and clinical trials are concordant with the good results these scaffolds received in our in vitro test.
This seems to prove the assumption that our new score can be a reliable tool to determine which
biomaterials are worth being further tested in in vivo experiments and subsequent clinical trials. Using
our new in vitro testing system research resources could be saved by saving money, time and animal
lives. Furthermore our score can be used to standardize biomaterial testing, thus making it possible to
objectively compare results amongst different working groups.
As described in the next paragraphs, our score incorporates the assessment of the most important
qualities of scaffolds for meniscus repair. According to several authors [28,29] scaffolds should have
the following qualities: biocompatibility, open pores to enable tissue ingrowth and properties for
cell adhesion.
Especially the quality of porosity is an essential feature for successful tissue engineering of the
meniscus with mesenchymal stem cell-filled scaffolds [30].
Therefore, our scoring system contains three single scoring items that are directly or indirectly
connected with the quality of the scaffold porosity: the quality of pore structure, the interconnectivity
of pores and the cell distribution in the scaffolds.
As mentioned above, biocompatibility is a vital feature for a successful biomaterial. Our testing
system thoroughly assesses the biocompatibility of the scaffolds with the scoring items of the in vitro
experiment: viability of cells and production of proteoglycans.
Furthermore it is important for the cells inside the scaffolds to not merely produce scar tissue but
to produce mechanically stable meniscus-like tissue. The dry mass of the human meniscus mainly
consists of collagen [31] and our chondrogenesis model is specifically set to enable production of
collagen II. Consequently, our score rewards high contents of collagen type II as this also shows
the successful differentiation of the MSCs. In contrast, collagen type I production rather hints to
undifferentiated scar tissue, which is why a low content of collagen type I is rewarded with a high
score in our testing system.
A recent review article gives an overview about the currently used scoring systems for meniscus
repair [32]. While none of these scoring systems are intended for the in vitro evaluation of biomaterial,
they nonetheless frequently analyze certain key tissue characteristics that are also assessed in our score.
These central tissue characteristics include cellularity, collagen formation, and proteoglycan content.
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The aspect of scaffold porosity has mostly been neglected in the described scoring systems. However,
we consider porosity to be a central aspect for scaffolds and, therefore, made it a big part of our score.
As demonstrated, our score covers the most important properties of a good biomaterial scaffold
for meniscus repair and therefore qualifies as a highly effective tool with a very accurate prediction
value for the assessment of new biomaterials. Our score assesses differences in key characteristics
that are vital for any type of scaffold; consequently, our score can be applied for testing any kind of
biomaterial that is intended for cell-enhanced meniscus repair. Our scoring system offers a thorough,
but easily reproducible, seven step evaluation that can help investigators to both objectify their results
and to compare the qualities of different biomaterials.
In biomaterial research a variety of animal types has been used, amongst others: rabbits, dogs,
and sheep. As our score relies on standardized in vitro conditions we eliminate the variability of results
that is involved when using different types of animals for in vivo studies.
Mesenchymal stem cells have been a focus of research as a source for tissue engineering, which is
why we used mesenchymal stem cells in our experiments. However, our scoring system could also be
used for a combination of scaffold with different cell types.
There are some limitations to our study, which we purposely tolerate for different reasons.
While biomechanics are an essential property of any biomaterial [33] our score does not examine
it. Biomechanics and biocompatibility should be assessed separately, as it facilitates identification
of parameters that have to be adjusted. Furthermore, a thorough test regime for the functional and
biomechanical analysis of scaffolds has already been described by Maher et al [26]. This test regime
can easily be combined with our scoring system, thus creating a complete evaluation of a biomaterial.
Another limitation of our study might be the relatively low-key use of quantification, software, and
special viability staining, as well as the relying on naked eye assessment. However, we wanted to create
a simple score that can quickly and easily be applied by any investigator without having to purchase
expensive dyes or software. Experienced meniscus investigators are capable of a reliable and objective
naked eye examination that gives valuable qualitative information. Our score possesses the advantage
to function not only with a relatively simple approach like presented in this study, but also with a
more quantified approach, as single scoring items could also be assessed with quantification software
or assays, if this is desired. For these reasons and despite its limitations our scoring system presents a
valuable novel tool for the evaluation of scaffolds. Our score gives a quick overview whether a newly
developed bio material is worth to proceed to further research steps for example in an in vivo setting.
Given the good results the Actifit® scaffold reached in our experiments it qualifies for
mesenchymal stem cell-based meniscus repair and should be further investigated in in vivo experiments
and clinical trials.
As mentioned above, cell-free scaffolds are currently used in clinics with promising results,
however, this approach could possibly be further enhanced by the addition of mesenchymal stem cells.
The ideal cell for cell-based meniscus repair should be autologous, obtainable in sufficient numbers
in a minimal-invasive procedure and it has to possess the ability to be expanded in tissue culture
and to produce stable fibrocartilaginous extracellular matrix [34]. These qualities are met by MSCs:
they are easily obtainable via bone marrow puncture [35], can be expanded in tissue culture without
losing their stem cell characteristics [36], and have shown the ability to produce fibrocartilaginous
extracellular matrix [18].
Several studies have shown a statistically significant benefit that resulted by loading a scaffold
with MSCs compared to cell-free scaffolds [18,19]. This benefit seems to originate from a dual role
of the MSCs in meniscus repair [17]. Firstly, MSCs could directly heal meniscus lesions, as they
can differentiate into fibro chondrocytes [37]. Secondly, MSCs could indirectly enhance meniscus
healing via secretion of bioactive substances [38] that promote self-healing. Furthermore, MSCs possess
immunoregulatory properties and could, thus, prevent tissue destruction and scar formation in injured
tissue [38]. Consequently, the use of MSCs to enhance scaffold-based meniscus repair seems to be a
promising approach.
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5. Conclusions
The new score we developed could be applied as a new standard for in vitro scaffold testing of
different biomaterials and, thus, save precious financial resources, as well as research animals and time.
The polyurethane scaffold showed excellent results in our in vitro test and seems to be a promising
biomaterial for tissue engineering with MSCs. In vivo studies with a mesenchymal stem cell-filled
Actifit® scaffold will determine whether this approach can be applied in clinics.
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